Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.40|
|52 Week High||US$3.84|
|52 Week Low||US$9.25|
|1 Month Change||-4.43%|
|3 Month Change||16.88%|
|1 Year Change||41.73%|
|3 Year Change||-66.81%|
|5 Year Change||69.28%|
|Change since IPO||-99.10%|
Recent News & Updates
|AMRN||US Biotechs||US Market|
Return vs Industry: AMRN exceeded the US Biotechs industry which returned 26.1% over the past year.
Return vs Market: AMRN exceeded the US Market which returned 35.3% over the past year.
Stable Share Price: AMRN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AMRN's weekly volatility (7%) has been stable over the past year.
About the Company
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers.
Amarin Fundamentals Summary
|AMRN fundamental statistics|
Is AMRN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMRN income statement (TTM)|
|Cost of Revenue||US$128.32m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.011|
|Net Profit Margin||0.70%|
How did AMRN perform over the long term?See historical performance and comparison
Is Amarin undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMRN ($5.4) is trading below our estimate of fair value ($13.67)
Significantly Below Fair Value: AMRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMRN is poor value based on its PE Ratio (494.5x) compared to the US Biotechs industry average (24.9x).
PE vs Market: AMRN is poor value based on its PE Ratio (494.5x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: AMRN is poor value based on its PEG Ratio (6.1x)
Price to Book Ratio
PB vs Industry: AMRN's PB Ratio (3.3x) is in line with the US Biotechs industry average.
How is Amarin forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRN's forecast earnings growth (81.2% per year) is above the savings rate (2%).
Earnings vs Market: AMRN's earnings (81.2% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AMRN's revenue (16.7% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: AMRN's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMRN is forecast to be unprofitable in 3 years.
How has Amarin performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRN has a high level of non-cash earnings.
Growing Profit Margin: AMRN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AMRN has become profitable over the past 5 years, growing earnings by 30.2% per year.
Accelerating Growth: AMRN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AMRN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: AMRN's Return on Equity (0.7%) is considered low.
How is Amarin's financial position?
Financial Position Analysis
Short Term Liabilities: AMRN's short term assets ($996.0M) exceed its short term liabilities ($370.4M).
Long Term Liabilities: AMRN's short term assets ($996.0M) exceed its long term liabilities ($29.2M).
Debt to Equity History and Analysis
Debt Level: AMRN is debt free.
Reducing Debt: AMRN currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: AMRN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: AMRN has no debt, therefore coverage of interest payments is not a concern.
What is Amarin current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Karim Mikhail (50 yo)
Mr. Karim Mikhail serves as President, Chief Executive Officer and Director at Amarin Corporation plc since August 01, 2021 and served as its Senior Vice President and Commercial Head of Europe since Augus...
Experienced Management: AMRN's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: AMRN's board of directors are seasoned and experienced ( 11.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Amarin Corporation plc's employee growth, exchange listings and data sources
- Name: Amarin Corporation plc
- Ticker: AMRN
- Exchange: NasdaqGM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.135b
- Shares outstanding: 395.30m
- Website: https://www.amarincorp.com
Number of Employees
- Amarin Corporation plc
- Grand Canal Docklands
- Block C
- Co. Dublin
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 22:02|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.